They act on the CDK-RB1-E2F pathway which is disrupted in cancer cells, and they are prescribed alone or, more often, together with drugs which prevent the downstream estrogen-dependent stimulation of cancer cells in most breast cancers [8]. Here, RB1 is linked to cancer.